<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02122809</url>
  </required_header>
  <id_info>
    <org_study_id>CAR101</org_study_id>
    <nct_id>NCT02122809</nct_id>
  </id_info>
  <brief_title>Phase I Study of Chiauranib in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Safety and Pharmacokinetics Study of Chiauranib in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chipscreen Biosciences, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chipscreen Biosciences, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this dose-escalation study is to assess the safety and tolerability of&#xD;
      treatment with Chiauranib administered orally over a range of doses in patients with advanced&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the tolerability and safety include adverse events,&#xD;
      vital signs, laboratory tests ,etc., of a range of doses of Chiauranib in solid tumor&#xD;
      patients, and to determine the dose limit toxicity and the maximum tolerable dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose-limiting toxicity (DLT)</measure>
    <time_frame>day 1-28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>An expected average of 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic profile of Chiauranib</measure>
    <time_frame>On day 1,8,15,22,25,26,27,28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of benefit</measure>
    <time_frame>An expected average of 8 months</time_frame>
    <description>clinical benefit rate (complete response (CR),partial response (PR),stable disease (SD) &gt; 8 weeks),duration of response (DOR),time to progression (TTP), or tumor marker improvement, if appropriate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile of Chiauranib</measure>
    <time_frame>On day 15,28</time_frame>
    <description>Plasma biomarkers: soluble vascular endothelial growth factor receptors (sVEGFR2), vascular endothelial growth factor (VEGF) Tumor tissue biomarkers: Aurora B, phospho-histone H3</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Chiauranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients take a single dose of Chiauranib capsules for the pharmacokinetic study,then off for 5 days before the first cycle begins. In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chiauranib</intervention_name>
    <description>Take orally</description>
    <arm_group_label>Chiauranib</arm_group_label>
    <other_name>CS2164</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological or cytological confirmation of advanced solid tumor, including non-small&#xD;
             cell lung cancer, colorectal cancer, ovarian cancer, renal cell carcinoma,&#xD;
             gastrointestinal stromal tumor, gastric cancer, et al;&#xD;
&#xD;
          2. Patients with advanced solid tumors refractory to standard therapy or for which no&#xD;
             standard therapy exists;&#xD;
&#xD;
          3. Body mass index (BMI) is between 18 and 28;&#xD;
&#xD;
          4. Age: 18~65 years;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;&#xD;
&#xD;
          6. Laboratory criteria are as follows:&#xD;
&#xD;
               1. Complete blood count: hemoglobin (Hb) ≥100g/L (no blood transfusion within 14&#xD;
                  days); absolute neutrophil count (ANC) ≥1.5×109/L ; platelets &gt;=100×109/L&#xD;
&#xD;
               2. Biochemistry test: serum creatinine &lt;=1.5×upper limit of normal (ULN); total&#xD;
                  bilirubin≦1.5×ULN; alanine aminotransferase / aspartate aminotransferase≦1.5×ULN;&#xD;
                  fasting triglyceride (TG) &lt;= 3.0 mmol/L; total cholesterol &lt;= 7.75 mmol/L&#xD;
&#xD;
               3. Coagulation test: International Normalized Ratio (INR) &lt; 1.5&#xD;
&#xD;
          7. Women of child-bearing potential should be non-lactating patients, and must agree to&#xD;
             use effective contraceptive methods prior to study entry, during study participation,&#xD;
             and up to 6 months following completion of therapy. A serum or urine pregnancy test&#xD;
             within 7 days before enrollment must be negative; Men must agree to use effective&#xD;
             contraceptive methods during study participation and up to 6 months following&#xD;
             completion of therapy;&#xD;
&#xD;
          8. Willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectation &lt; 3 months;&#xD;
&#xD;
          2. Subjects received anti-cancer therapy (including chemotherapy, radiotherapy, targeted&#xD;
             therapy and endocrine therapy, et al) within 4 weeks prior to study entry; Subjects&#xD;
             received nitrosoureas or mitomycin chemotherapy within 6 weeks prior to study entry;&#xD;
&#xD;
          3. Have uncontrolled or significant cardiovascular disease, including:&#xD;
&#xD;
               1. Myocardial infarction (&lt; the last 12 months)&#xD;
&#xD;
               2. Uncontrolled angina (&lt; the last 6 months)&#xD;
&#xD;
               3. Congestive heart failure (&lt; the last 6 months), or Left Ventricular Ejection&#xD;
                  Fraction (LVEF) &lt; 50% prior to study entry&#xD;
&#xD;
               4. History of any significant ventricular arrhythmias (e.g., ventricular&#xD;
                  tachycardia, ventricular fibrillation, or TdP)&#xD;
&#xD;
               5. History of significant QT interval prolongation, or Corrected QT Interval (QTc) &gt;&#xD;
                  450 ms prior to study entry&#xD;
&#xD;
               6. History of cerebrovascular accident&#xD;
&#xD;
               7. Symptomatic coronary heart disease requiring treatment with agents&#xD;
&#xD;
               8. Uncontrolled hypertension (&gt; 140/90 mmHg) by single agent;&#xD;
&#xD;
          4. Have active bleeding , current thrombotic disease, or patients with bleeding potential&#xD;
             receiving anticoagulation therapy;&#xD;
&#xD;
          5. History of deep vein thrombosis or pulmonary embolism;&#xD;
&#xD;
          6. Have unsolved toxicities (&gt; grade 1) from prior anti-cancer therapy;&#xD;
&#xD;
          7. Have clinical significant gastrointestinal abnormality, e.g., unable to swallow,&#xD;
             chronic diarrhea, ileus, that would impair the ingestion,transportation or absorption&#xD;
             of oral agents, or patients undergone gastrectomy;&#xD;
&#xD;
          8. Have symptomatic brain metastasis;&#xD;
&#xD;
          9. History of organ transplantation;&#xD;
&#xD;
         10. Proteinuria positive;&#xD;
&#xD;
         11. Congenital or acquired immunodeficiency, active infections;&#xD;
&#xD;
         12. Any mental or cognitive disorder, that would impair the ability to understand the&#xD;
             informed consent document or the operation and compliance of study;&#xD;
&#xD;
         13. Any other condition which is inappropriate for the study in the opinion of the&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chiauranib, advanced solid tumors, phase 1 study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chiauranib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

